Ginkgo Bioworks Holdings (DNA) Total Non-Current Liabilities (2019 - 2026)

Ginkgo Bioworks Holdings (DNA) has 8 years of Total Non-Current Liabilities data on file, last reported at $568.2 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 9.9% year-over-year to $568.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $568.2 million (down 9.9% YoY) and the FY2025 annual result came in at $588.2 million, down 8.78% from the prior year.
• Total Non-Current Liabilities declined to $568.2 million in Q1 2026, from $588.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $780.3 million in Q1 2023 to a low of $391.2 million in Q3 2022.
• A 5-year average of $619.1 million and a median of $612.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 217.73% — and 2023, when it declined 29.55%.
• Tracing DNA's Total Non-Current Liabilities over 5 years: stood at $771.9 million in 2022, then decreased by 29.55% to $543.8 million in 2023, then climbed by 18.59% to $644.8 million in 2024, then declined by 8.78% to $588.2 million in 2025, then slipped by 3.41% to $568.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $568.2 million (Q1 2026), $588.2 million (Q4 2025), and $612.2 million (Q3 2025), per Business Quant data.